Frequently used quantitative polymerase chain reaction–based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 115, 67-75
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Existing and Emerging Technologies for Tumor Genomic ProfilingJournal of Clinical Oncology, 2013
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic CharacteristicsMolecular Cancer Therapeutics, 2013
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase InhibitorsJournal of Thoracic Oncology, 2013
- EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung AdenocarcinomaClinical Cancer Research, 2012
- Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung CancerClinical Cancer Research, 2011
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerNew England Journal of Medicine, 2009
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLOS Medicine, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLOS Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004